Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence
Abstract This study evaluated if iodine-125 brachytherapy prophylaxis after radiofrequency ablation (RFA) prolongs time to recurrence (TTR) and overall survival (OS) of patients in high risk of locoregional hepatocellular carcinoma (HCC) recurrence. 116 patients with total tumor necrosis after RFA w...
Guardado en:
Autores principales: | Jian-Fei Tu, Ya-Hui Ding, Li Chen, Xi-Hui Ying, Deng-Ke Zhang, Fa-Zong Wu, Zhong-Wei Zhao, Jian-Song Ji, Wang-Gang Zhang, Hai Zou |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b4b0f42caab1422991ab01580082beb5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective Interventricular Septal Radiofrequency Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?
por: Qiang Liu, et al.
Publicado: (2021) -
Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
por: Qin Jiang, et al.
Publicado: (2021) -
Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma
por: Bin Chai, et al.
Publicado: (2021) -
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas
por: Ghassemi F, et al.
Publicado: (2020) -
Management of spontaneously ruptured hepatocellular carcinomas in the radiofrequency ablation era.
por: Tan To Cheung, et al.
Publicado: (2014)